Findings indicate that excessive somatostatin inhibits glucagon secretion in type 1 diabetes, offering a novel target for hypoglycemia management strategies.
AdAlta, SYNthesis to form AdCella for advanced cancer treatments
Share this article AdCella will focus on identifying partners with the capability to develop multi-functional cellular immunotherapies. Credit: Lightspring/Shutterstock.com. Australian biotechnology company AdAlta has signed